Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,849 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03515824 | Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001) | terminated | Phase 1 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 2 | Mar 9, 2021 | clinicaltrials |
| NCT03380689 | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer(SIRB2) | withdrawn | Phase 1 | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 8, 2021 | clinicaltrials |
| NCT02953782 | Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | completed | Phase 1 / Phase 2 | 78 | Gilead SciencesINDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01801930 | A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer | completed | Phase 1 | 24 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03542214 | Calcium Electroporation for the Treatment of Colorectal Cancer | completed | Phase 1 | 6 | Zealand University HospitalOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01927341 | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | completed | Phase 1 / Phase 2 | 53 | PfizerINDUSTRY | 7 | Feb 18, 2021 | clinicaltrials |
| NCT02008383 | Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer(CaboMAb) | completed | Phase 1 | 29 | John Strickler, M.D.OTHER | 1 | Feb 12, 2021 | clinicaltrials |
| NCT03977090 | Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer | unknown | Phase 1 | 21 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04162535 | Elucidation of the Mechanisms and Effects of Certain Anesthetic Interventions on Digestive Cancer Patients Subjected to Surgery | unknown | Phase 1 | 40 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT01781403 | Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer | completed | Phase 1 | 22 | Asan Medical CenterOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT00578396 | Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention | withdrawn | Phase 1 | 0 | University of California, IrvineOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT01407107 | Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer | completed | Phase 1 | 13 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT04110093 | Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer | unknown | Phase 1 / Phase 2 | 120 | Shanghai Changzheng HospitalOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT03985891 | The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer(JSFOL) | unknown | Phase 1 / Phase 2 | 40 | Xiangya Hospital of Central South UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03081494 | Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 11, 2020 | clinicaltrials |
| NCT00969046 | Dose-Escalation Study in Advanced Colon Cancer Patients | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT01068483 | Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | completed | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT04231552 | Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer | unknown | Phase 1 / Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03692429 | alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells(alloSHRINK) | recruiting | Phase 1 | 49 | Celyad Oncology SAINDUSTRY | 2 | Nov 20, 2020 | clinicaltrials |
| NCT04006301 | First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation | completed | Phase 1 | 10 | Janssen Research & Development, LLCINDUSTRY | 2 | Nov 6, 2020 | clinicaltrials |
| NCT02010567 | Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer | terminated | Phase 1 / Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | withdrawn | Phase 1 | 0 | Jiujiang University Affiliated HospitalOTHER_GOV | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | terminated | Phase 1 | 5 | Fore BiotherapeuticsINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02906059 | Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | completed | Phase 1 | 7 | NYU Langone HealthOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT02178644 | Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer | completed | Phase 1 | 29 | Yale UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01896856 | Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 118 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Oct 6, 2020 | clinicaltrials |
| NCT03152565 | Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients(AVEVAC) | completed | Phase 1 / Phase 2 | 28 | Grupo Espanol Multidisciplinario del Cancer DigestivoOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT03295084 | Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors | completed | Phase 1 | 39 | Dorte NielsenOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03189030 | Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer | terminated | Phase 1 | 28 | Aduro Biotech, Inc.INDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT01681472 | PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer | completed | Phase 1 / Phase 2 | 32 | Isofol Medical ABINDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | terminated | Phase 1 | 16 | Seagen Inc.INDUSTRY | 1 | Sep 17, 2020 | clinicaltrials |
| NCT00959127 | A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer | completed | Phase 1 | 93 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 16, 2020 | clinicaltrials |
| NCT03029988 | An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases. | terminated | Phase 1 | 3 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Sep 10, 2020 | clinicaltrials |
| NCT01189942 | A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer | completed | Phase 1 | 18 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 9, 2020 | clinicaltrials |
| NCT01397305 | An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer | completed | Phase 1 / Phase 2 | 24 | Isofol Medical ABINDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02244632 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | completed | Phase 1 / Phase 2 | 105 | Isofol Medical ABINDUSTRY | 4 | Sep 9, 2020 | clinicaltrials |
| NCT03384316 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | terminated | Phase 1 | 27 | Famewave Ltd.INDUSTRY | 2 | Aug 27, 2020 | clinicaltrials |
| NCT04126655 | Modelle 001, TS-inhibition in Colorectal Liver Metastases Comparing Arfolitixorin and Calciumfolinate | unknown | Phase 1 / Phase 2 | 30 | Vastra Gotaland RegionOTHER_GOV | 1 | Aug 27, 2020 | clinicaltrials |
| NCT01302613 | Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma | withdrawn | Phase 1 / Phase 2 | 0 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT01634685 | A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma | completed | Phase 1 | 15 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT03031691 | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | completed | Phase 1 | 7 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT03035253 | A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer | terminated | Phase 1 | 16 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 11, 2020 | clinicaltrials |
| NCT00003225 | Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 23 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | terminated | Phase 1 | 17 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03507998 | Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors | unknown | Phase 1 | 39 | Curegenix Inc.INDUSTRY | 1 | Jul 24, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Mar 9, 2021source: clinicaltrials